A Phase I Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 120
- 试验地点
- 11
- 主要终点
- Assess the toxicity of hypofractionated radiation therapy as definitive treatment for low and intermediate risk prostate cancer.
研究概览
简要总结
The purpose of this study is to test the safety of a new type of IG-IMRT called "ultra-hypofractionated IG-IMRT" where a higher dose of radiation is given to the tumor during each treatment day. Since higher doses of radiation are used each day, the total number of treatment days needed to complete this type of radiation is only five instead of the 45-48 treatments currently used. Treatment takes place every other day and is complete after 2 weeks. If the patient decides to get this treatment, they will come in for 5 treatments. This is different from the 48 treatments they would get normally.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Eligibility is not restricted to MSKCC to confirm biopsy/diagnosis. Participating institution testing is sufficient.
- •Low and intermediate risk prostate cancer patients will be eligible for this study. Risk groups will be assigned as per NCCN guidelines.
- •Low risk patients will be defined as:
- •PSA < or = to 10 ng/ml and
- •Gleason score = 6 and
- •Clinical Stage < or = to T2a
- •Intermediate risk patients will be defined as:
- •PSA 10-20 ng/ml or
- •Gleason score = 7 or
- •Clinical stage T2b/T2c
- •Additionally, patients will be required to meet the following criteria:
- •Age > or = to 18
- •KPS > or = to 70
- •Pre-treatment endorectal coil MRI or CT (MRI preferred) at MSKCC showing no definite evidence of radiographic T3, T4, or N1 disease
- •Prostate size < or = to 60 cc
- •International Prostate Symptom Score < or = to 15
排除标准
- •Prior androgen deprivation therapy for prostate cancer
- •Elective pelvic lymph node irradiation
- •KPS < 70
- •Pelvic MRI or CT (MRI preferred) evidence of radiographic T3, T4 or N1 disease
- •Presence of distant metastasis as determined by:
- •o alkaline phosphatase > or = to ULN or
- •whole body bone scan positive for osseous metastases
- •Prior history of transurethral resection of the prostate
- •Prior history of chronic prostatitis
- •Prior history of urethral stricture
- •Prior history of pelvic irradiation
- •History of inflammatory bowel disease
- •Unable to give informed consent
- •Unable to complete quality of life questionnaires Abnormal complete blood count. Any of the following
- •Platelet count less than 75,000/ml
- •Hb level less than 10 gm/dl
- •WBC less than 3.5/ml
- •Abnormal renal function tests (creatinine > 1.5)
研究组 & 干预措施
Radiation
Patients enrolled in the study will undergo image-guided, intensity-modulated radiotherapy using the same equipment, techniques, and treatment-planning procedures as currently practiced as MSKCC. MSKCC patients will have the option of continued follow-up through MSKCC's established Prostate Survivorship Clinic for an indefinite period of time, meaning patients enrolled in the protocol will be encouraged to remain at MSKCC for life-long follow-up after their treatment. The standard assessments obtained in the Survivorship Clinic will not be altered. All protocol relevant data collected at these visits through month 60 will be used for protocol analysis.
干预措施: Hypofractionated, image-guided, intensity-modulated external beam radiation (Radiation)
结局指标
主要结局
Assess the toxicity of hypofractionated radiation therapy as definitive treatment for low and intermediate risk prostate cancer.
时间窗: With at least one status check visit during the course of treatment.
次要结局
- Evaluate the effect of treatment on sexual function.(1, 3, & 6 months (+/- 4 weeks) Months 6 - 36 every 6 months (+/- 4 weeks))
- Evaluate post-treatment PSA kinetics and incidence of PSA relapse free survival.(1, 3, & 6 months (+/- 4 weeks) Months 6 - 36 every 6 months (+/- 4 weeks))
- Evaluate pathologic response rates at 24-36 months via repeat biopsy.(24-36 months post treatment)